Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/immunotherapy-in-chronic-lymphocytic-leukaemia-cll-UjE1G1K9XY
References (99)
-
(2013)
This academic group have elegantly described the T cell dysfunction that evolves in patients with CLL and outlined how this might be overcome using checkpoint blockade and IMiDs -
J. Teeling, W. Mackus, L. Wiegman, J. Brakel, S. Beers, R. French, T. Meerten, S. Ebeling, T. Vink, J. Slootstra, P. Parren, M. Glennie, J. Winkel (2006)
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201The Journal of Immunology, 177
-
R. Lapalombella, A. Gowda, Trupti Joshi, Najma Mehter, C. Cheney, A. Lehman, Ching Chen, A. Johnson, M. Caligiuri, S. Tridandapani, N. Muthusamy, J. Byrd (2009)
The humanized CD40 antibody SGN‐40 demonstrates pre‐clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemiaBritish Journal of Haematology, 144
-
M. Xia, G. Hale, M. Lifely, M. Ferguson, D. Campbell, L. Packman, H. Waldmann (1993)
Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.The Biochemical journal, 293 ( Pt 3)
-
T. Robak, A. Dmoszyńska, P. Solal-Céligny, K. Warzocha, J. Loscertales, J. Catalano, B. Afanasiev, L. Larratt, C. Geisler, M. Montillo, Ilya Zyuzgin, P. Ganly, C. Dartigeas, A. Rosta, Jörg Maurer, M. Mendila, M. Saville, N. Valente, M. Wenger, S. Moiseev (2010)
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 10
-
(2006)
Alemtuzumab induces caspaseindependent cell death in human chronic lymphocytic leukemia cells through a lipid raftdependent mechanism -
(2015)
The study is a review of the current evidence and outcomes in CLL using CAR-T cells and reduced intensity conditioning for allogeneic transplant -
H. Nückel, U. Frey, A. Röth, U. Dührsen, W. Siffert (2005)
Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.European journal of pharmacology, 514 2-3
-
Available from: http://www.cancer.gov/dictionary?CdrID=45729 -
(2015)
The paper is a comprehensive nature review of the historical development of immunotherapy in the field of haematological malignancies and future directions in this field -
David Porter, N. Frey, J. Melenhorst, W. Hwang, S. Lacey, P. Shaw, A. Chew, S. Grupp, James Capobianchi, J. Gilmore, M. Kalos, M. Litchman, Lester Lledo, A. Loren, Y. Mahnke, K. Marcucci, Holly McConville, A. Shen, P. Wood, Zhaohui Zheng, Bruce Levine, Carl June (2013)
Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLLBlood, 122
-
J. Castillo, E. Winer, P. Quesenberry (2008)
Newer monoclonal antibodies for hematological malignancies.Experimental hematology, 36 7
-
A. Viardot, M. Goebeler, M. Pfreundschuh, N. Adrian, M. Libicher, Evelyn Degenhard, J. Stieglmaier, A. Zhang, D. Nagorsen, R. Bargou (2013)
Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE®) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaBlood, 122
-
J. Hulkkonen, L. Vilpo, M. Hurme, Juhani Vilpo (2002)
Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalitiesLeukemia, 16
-
M Hallek (2015)
Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatmentAm J Hematol, 90
-
S. Sandhu, S. Mulligan (2015)
Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemiaHaematologica, 100
-
S. Herter, F. Herting, O. Mundigl, Inja Waldhauer, Tina Weinzierl, T. Fauti, G. Muth, Doris Ziegler-Landesberger, Erwin Puijenbroek, Sabine Lang, M. Duong, Lina Reslan, C. Gerdes, T. Friess, Ute Baer, H. Burtscher, M. Weidner, C. Dumontet, P. Umaña, G. Niederfellner, M. Bacac, C. Klein (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft ModelsMolecular Cancer Therapeutics, 12
-
(2014)
This paper is a detailed review of immunotherapeutic approaches used in the treatment of malignancy -
S. Grupp, M. Kalos, D. Barrett, R. Aplenc, David Porter, S. Rheingold, D. Teachey, A. Chew, B. Hauck, J. Wright, Michael Milone, Bruce Levine, Carl June (2013)
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.The New England journal of medicine, 368 16
-
A. Kater, S. Tonino, A. Egle, A. Ramsay (2014)
How does lenalidomide target the chronic lymphocytic leukemia microenvironment?Blood, 124 14
-
K. Fischer, P. Cramer, R. Busch, S. Stilgenbauer, J. Bahlo, C. Schweighofer, S. Böttcher, P. Staib, M. Kiehl, M. Eckart, G. Kranz, V. Goede, T. Elter, A. Bühler, D. Winkler, M. Kneba, H. Döhner, B. Eichhorst, M. Hallek, C. Wendtner (2011)
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 26
-
S. Herter, C. Klein, P. Umaña, M. Bacac (2013)
Obinutuzumab (GA101) More Potently Engages Phagocytic-Lineage Cells Resulting In Enhanced Monocyte and Macrophage Activity When Compared To Rituximab and OfatumumabBlood, 122
-
J. Riches, J. Davies, F. McClanahan, Rewas Fatah, S. Iqbal, S. Agrawal, A. Ramsay, J. Gribben (2013)
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.Blood, 121 9
-
D. Gladstone, M. André, J. Zaucha, S. Assouline, Naresh Bellam, N. Cascavilla, E. Jourdan, A. Panwalkar, C. Patti, C. Schulte, F. Zaja, T. Goswami, N. Elgeioushi, K. Streicher, H. Bao, D. Spaner (2014)
Phase 2 Open-Label study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL -
F. Ricci, A. Tedeschi, E. Morra, M. Montillo (2009)
Fludarabine in the treatment of chronic lymphocytic leukemia: a reviewTherapeutics and Clinical Risk Management, 5
-
(2012)
Altered immune cells beat leukemia, in The New York Times -
M. Hallek (2015)
CME Information: Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment -
M. Beyer, M. Kochanek, Kamruz Darabi, A. Popov, M. Jensen, E. Endl, P. Knolle, Roman Thomas, M. Bergwelt-Baildon, S. Debey, M. Hallek, J. Schultze (2005)
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.Blood, 106 6
-
(2012)
Altered immune cells beat leukemia -
J. Golay, M. Manganini, A. Rambaldi, M. Introna (2004)
Effect of alemtuzumab on neoplastic B cells.Haematologica, 89 12
-
T. Sher, K. Miller, D. Lawrence, A. Whitworth, F. Hernandez-Ilizaliturri, M. Czuczman, Austin Miller, William Lawrence, S. Bilgrami, R. Sood, M. Wood, A. Block, Kelvin Lee, A. Chanan-Khan (2010)
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogeneticsLeukemia & Lymphoma, 51
-
J. Gribben (2009)
Stem cell transplantation in chronic lymphocytic leukemia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 15 1 Suppl
-
O. Press, Janet Howell-Clark, S. Anderson, I. Bernstein (1994)
Retention of B-cell-specific monoclonal antibodies by human lymphoma cells.Blood, 83 5
-
P. Dreger, P. Corradini, E. Kimby, M. Michallet, D. Milligan, J. Schetelig, W. Wiktor-Jedrzejczak, D. Niederwieser, M. Hallek, E. Montserrat (2007)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensusLeukemia, 21
-
Jennifer Brown, J. Abramson, E. Hochberg, Evgeny Mikler, V. Dalton, L. Werner, Hazel Reynolds, C. Thompson, Sean McDonough, Y. Kuang, J. Ritz, D. Neuberg, A. Freedman (2010)
A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLLLeukemia, 24
-
(2015)
This study is an overview of the treatment evolution in CLL with up-to-date therapeutic strategies including newly licenced agents -
G. Lozanski, N. Heerema, I. Flinn, Lisa Smith, J. Harbison, J. Webb, M. Moran, M. Lucas, T. Lin, M. Hackbarth, J. Proffitt, D. Lucas, M. Grever, J. Byrd (2004)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.Blood, 103 9
-
A. Pinto, G. Corazzelli, R. Filippi (2012)
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical responseCancer, 118
-
M. Milone, J. Fish, C. Carpenito, R. Carroll, G. Binder, D. Teachey, M. Samanta, M. Lakhal, B. Gloss, G. Danet-Desnoyers, D. Campana, J. Riley, S. Grupp, C. June (2009)
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.Molecular therapy : the journal of the American Society of Gene Therapy, 17 8
-
I. Khouri, R. Bassett, N. Poindexter, S. O'brien, C. Bueso-Ramos, Y. Hsu, A. Ferrajoli, M. Keating, R. Champlin, M. Fernández-Viña (2011)
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemiaCancer, 117
-
(2010)
The clinical application ofmonoclonal antibodies in chronic lymphocytic leukemia -
E. Mössner, P. Brünker, S. Moser, U. Püntener, C. Schmidt, S. Herter, R. Grau, C. Gerdes, Adam Nopora, Erwin Puijenbroek, C. Ferrara, P. Sondermann, Christian Jäger, Pamela Strein, G. Fertig, T. Friess, Christine Schüll, S. Bauer, J. Porto, Christopher Nagro, K. Dabbagh, M. Dyer, S. Poppema, C. Klein, P. Umaña (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.Blood, 115 22
-
(2014)
Classification of current anticancer immunotherapies. Oncotarget. 2014;5(24):12472–508.This paper is a detailed review of immunotherapeutic approaches used in the treatment of malignancy -
M. Patz, P. Isaeva, Nche Forcob, Bianka Müller, L. Frenzel, C. Wendtner, C. Klein, P. Umaña, M. Hallek, Günter Krause (2011)
Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsBritish Journal of Haematology, 152
-
J. Byrd, J. Pagel, F. Awan, A. Forero, I. Flinn, D. Deauna-Limayo, S. Spurgeon, L. Andritsos, A. Gopal, J. Leonard, A. Eisenfeld, J. Bannink, S. Stromatt, R. Furman (2014)
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.Blood, 123 9
-
(2013)
Open-label phase 2 study of the bispecific T-cell engager (BiTE¬AE) blinatumomab in patients with relapsed/ refractory diffuse large B-cell lymphoma -
J. Byrd, Jennifer Brown, S. O'brien, J. Barrientos, N. Kay, N. Reddy, S. Coutre, C. Tam, S. Mulligan, U. Jaeger, S. Devereux, P. Barr, R. Furman, T. Kipps, F. Cymbalista, C. Pocock, P. Thornton, F. Caligaris‐cappio, T. Robak, J. Delgado, S. Schuster, M. Montillo, A. Schuh, S. Vos, D. Gill, A. Bloor, C. Dearden, C. Moreno, Jeffrey Jones, A. Chu, M. Fardis, J. Mcgreivy, F. Clow, D. James, P. Hillmen (2014)
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.The New England journal of medicine, 371 3
-
Y. Hijazi, M. Klinger, A. Schub, Benjamin Wu, Min Zhu, P. Kufer, A. Wolf, D. Nagorsen (2013)
Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL).Journal of Clinical Oncology, 31
-
T. Tedder, M. Inaoki, Shin'ichi Sato (1997)
The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity.Immunity, 6 2
-
M. Cragg, C. Walshe, Andrey Ivanov, M. Glennie (2005)
The biology of CD20 and its potential as a target for mAb therapy.Current directions in autoimmunity, 8
-
J. Byrd, T. Kipps, I. Flinn, M. Cooper, O. Odenike, J. Bendiske, J. Rediske, S. Bilic, J. Dey, J. Baeck, S. O'brien (2012)
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemiaLeukemia & Lymphoma, 53
-
Xiaobin Zhao, R. Lapalombella, Trupti Joshi, C. Cheney, A. Gowda, M. Hayden-Ledbetter, P. Baum, T. Lin, D. Jarjoura, A. Lehman, Donna Kussewitt, Robert Lee, M. Caligiuri, S. Tridandapani, N. Muthusamy, J. Byrd (2007)
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.Blood, 110 7
-
K. Giannopoulos, M. Schmitt, M. Kowal, P. Własiuk, A. Bojarska-Junak, Jinfei Chen, J. Roliński, A. Dmoszyńska (2008)
Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia.Oncology reports, 20 3
-
P. Hillmen, T. Robak, A. Janssens, K. Babu, J. Kłoczko, S. Grosicki, M. Doubek, P. Panagiotidis, E. Kimby, A. Schuh, A. Pettitt, T. Boyd, M. Montillo, I. Gupta, Oliver Wright, I. Dixon, J. Carey, Chai-Ni Chang, S. Lisby, A. McKeown, F. Offner (2015)
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialThe Lancet, 385
-
P. Dreger, J. Schetelig, N. Andersen, P. Corradini, M. Gelder, J. Gribben, E. Kimby, M. Michallet, C. Moreno, S. Stilgenbauer, E. Montserrat (2014)
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Blood, 124 26
-
Christine Chen, P. Bergsagel, Harminder Paul, W. Xu, A. Lau, N. Dave, V. Kukreti, E. Wei, Chungyee Leung-Hagesteijn, Zhi Li, Joseph Brandwein, M. Pantoja, J. Johnston, S. Gibson, Tiffany Hernandez, D. Spaner, S. Trudel (2011)
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 9
-
J. Woyach, F. Awan, I. Flinn, J. Berdeja, Elizabeth Wiley, Sharmeen Mansoor, Ying Huang, G. Lozanski, P. Foster, J. Byrd (2014)
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL.Blood, 124 24
-
D. Maloney, Barbara Smith, Andrea Rose (2002)
Rituximab: mechanism of action and resistance.Seminars in oncology, 29 1 Suppl 2
-
A. Mato, D. Porter (2015)
A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs.Blood, 126 4
-
R. Brentjens, M. Davila, I. Rivière, Jae Park, Xiuyan Wang, L. Cowell, S. Bartido, J. Stefanski, Clare Taylor, M. Olszewska, Oriana Bórquez-Ojeda, Jinrong Qu, Teresa Wasielewska, Q. He, Y. Bernal, I. Rijo, C. Hedvat, R. Kobos, K. Curran, P. Steinherz, J. Jurcic, T. Rosenblat, P. Maslak, M. Frattini, M. Sadelain (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 5
-
J. Gribben, D. Zahrieh, K. Stephans, L. Bartlett-Pandite, E. Alyea, D. Fisher, A. Freedman, P. Mauch, R. Schlossman, L. Sequist, R. Soiffer, B. Marshall, D. Neuberg, J. Ritz, L. Nadler (2005)
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.Blood, 106 13
-
S. Jaglowski, L. Alinari, R. Lapalombella, N. Muthusamy, J. Byrd (2010)
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Blood, 116 19
-
(2010)
Rituximab in chronic lymphocytic leuke -
L. Galluzzi, E. Vacchelli, J. Pedro, A. Buqué, L. Senovilla, E. Baracco, N. Bloy, F. Castoldi, J. Abastado, P. Agostinis, R. Apte, Fernando Aranda, M. Ayyoub, P. Beckhove, J. Blay, L. Bracci, A. Caignard, C. Castelli, F. Cavallo, Estaban Celis, V. Cerundolo, A. Clayton, M. Colombo, L. Coussens, M. Dhodapkar, A. Eggermont, D. Fearon, W. Fridman, J. Fucikova, D. Gabrilovich, J. Galon, Abhishek Garg, F. Ghiringhelli, G. Giaccone, E. Gilboa, S. Gnjatic, A. Hoos, A. Hosmalin, D. Jäger, P. Kalinski, K. Kärre, O. Kepp, R. Kiessling, J. Kirkwood, E. Klein, A. Knuth, C. Lewis, R. Liblau, M. Lotze, E. Lugli, J. Mach, F. Mattei, D. Mavilio, I. Melero, C. Melief, E. Mittendorf, L. Moretta, Adekunke Odunsi, H. Okada, A. Palucka, M. Peter, K. Pienta, A. Porgador, G. Prendergast, G. Rabinovich, N. Restifo, N. Rizvi, C. Sautès-Fridman, H. Schreiber, B. Seliger, H. Shiku, B. Silva-Santos, M. Smyth, D. Speiser, R. Spíšek, P. Srivastava, J. Talmadge, E. Tartour, S. Burg, B. Eynde, R. Vile, H. Wagner, J. Weber, T. Whiteside, J. Wolchok, L. Zitvogel, W. Zou, G. Kroemer (2014)
Classification of current anticancer immunotherapiesOncotarget, 5
-
D. Gladstone, M. André, J. Zaucha, S. Assouline, Naresh Bellam, N. Cascavilla, E. Jourdan, A. Panwalkar, C. Patti, C. Schulte, F. Zaja, T. Goswami, N. Elgeioushi, K. Streicher, H. Bao, D. Spaner (2014)
Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic LeukemiaBlood, 124
-
S. O'brien (2015)
VIII. Treatment of chronic lymphocytic leukaemia, where are we heading?Hematological Oncology, 33
-
G. Cartron, H. Watier, J. Golay, P. Solal-Céligny (2004)
From the bench to the bedside: ways to improve rituximab efficacy.Blood, 104 9
-
G. Plosker, D. Figgitt (2003)
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.Drugs, 63 8
-
R. Furman, A. Forero-Torres, A. Shustov, J. Drachman (2010)
A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemiaLeukemia & Lymphoma, 51
-
M. Luqman, S. Klabunde, Karen Lin, G. Georgakis, A. Cherukuri, J. Holash, C. Goldbeck, Xiaomei Xu, E. Kadel, S. Lee, S. Aukerman, B. Jallal, N. Aziz, W. Weng, W. Wierda, S. O’Brien, A. Younes (2008)
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.Blood, 112 3
-
K. Ardeshna, W. Qian, Paul Smith, Nivette Braganca, L. Lowry, P. Patrick, J. Warden, L. Stevens, C. Pocock, F. Miall, D. Cunningham, J. Davies, A. Jack, R. Stephens, J. Walewski, B. Ferhanoğlu, K. Bradstock, D. Linch (2014)
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.The Lancet. Oncology, 15 4
-
F. McClanahan, J. Riches, Shaun Miller, William Day, E. Kotsiou, D. Neuberg, C. Croce, M. Capasso, J. Gribben (2015)
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.Blood, 126 2
-
V. Goede, K. Fischer, A. Engelke, R. Schlag, S. Leprêtre, L. Montero, M. Montillo, Christopher Fegan, E. Asikanius, Kathryn Humphrey, G. Fingerle-Rowson, Michael Hallek (2015)
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 studyLeukemia, 29
-
Idit Sagiv-Barfi, H. Kohrt, D. Czerwinski, Patrick Ng, B. Chang, R. Levy (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITKProceedings of the National Academy of Sciences, 112
-
R. Brentjens (2013)
with Chemotherapy-Refractory Acute Lymphoblastic Leukemia CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults -
(1982)
Randomized, phase II dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed -
C. Turtle, D. Sommermeyer, C. Berger, M. Hudecek, D. Shank, Natalia Steevens, Tanya Budiarto, Mandana Karimi, Colette Chaney, Anna DeVito, S. Heimfeld, M. Jensen, S. Riddell, D. Maloney (2014)
Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset CompositionBlood, 124
-
P. Bachireddy, U. Burkhardt, M. Rajasagi, Catherine Wu (2015)
Haematological malignancies: at the forefront of immunotherapeutic innovationNature Reviews Cancer, 15
-
W. Lesterhuis, J. Haanen, C. Punt (2011)
Cancer immunotherapy – revisitedNature Reviews Drug Discovery, 10
-
M. Topp, N. Gökbuget, A. Stein, G. Zugmaier, S. O'brien, R. Bargou, H. Dombret, A. Fielding, L. Heffner, R. Larson, S. Neumann, R. Foà, M. Litzow, J. Ribera, A. Rambaldi, G. Schiller, M. Brüggemann, H. Horst, C. Holland, Catherine Jia, T. Maniar, B. Huber, D. Nagorsen, S. Forman, H. Kantarjian (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.The Lancet. Oncology, 16 1
-
M. Hallek, K. Fischer, G. Fingerle-Rowson, A. Fink, R. Busch, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. Grünhagen, Matthias Bergmann, J. Catalano, P. Zinzani, F. Caligaris‐cappio, J. Seymour, A. Berrebi, U. Jäger, B. Cazin, M. Trněný, A. Westermann, C. Wendtner, B. Eichhorst, P. Staib, A. Bühler, D. Winkler, T. Zenz, S. Böttcher, M. Ritgen, M. Mendila, M. Kneba, H. Döhner, S. Stilgenbauer (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 376
-
A. Ramsay, R. Evans, S. Kiaii, L. Svensson, N. Hogg, J. Gribben (2013)
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.Blood, 121 14
-
S. Stilgenbauer, T. Zenz, D. Winkler, A. Bühler, R. Schlenk, S. Groner, R. Busch, M. Hensel, U. Dührsen, J. Finke, P. Dreger, U. Jäger, E. Lengfelder, K. Hohloch, U. Söling, R. Schlag, M. Kneba, M. Hallek, H. Döhner (2009)
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 24
-
P. Greaves, J. Gribben (2013)
The role of B7 family molecules in hematologic malignancy.Blood, 121 5
-
E. Montserrat (2003)
Rituximab in chronic lymphocytic leukemia.Seminars in oncology, 30 1S2
-
J. Uchida, Youngkyun Lee, M. Hasegawa, Yinghua Liang, Alice Bradney, J. Oliver, K. Bowen, D. Steeber, K. Haas, J. Poe, T. Tedder (2004)
Mouse CD20 expression and function.International immunology, 16 1
-
A. Ramsay, A. Clear, Rewas Fatah, J. Gribben (2012)
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.Blood, 120 7
-
F. McClanahan, Bola Hanna, Shaun Miller, A. Clear, P. Lichter, J. Gribben, M. Seiffert (2015)
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.Blood, 126 2
-
NCI Dictionary of Cancer Terms -
J. Westin, F. Chu, Min Zhang, L. Fayad, L. Kwak, N. Fowler, J. Romaguera, F. Hagemeister, M. Fanale, F. Samaniego, Lei Feng, V. Baladandayuthapani, Zhiqiang Wang, Wencai Ma, Yanli Gao, Michael Wallace, L. Vence, L. Radvanyi, T. Muzzafar, R. Rotem‐Yehudar, R. Davis, S. Neelapu (2014)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.The Lancet. Oncology, 15 1
-
(2014)
Classification of current anticancer immunotherapies This paper is a detailed review of immunotherapeutic approaches used in the treatment of malignancy -
A. Mone, C. Cheney, A. Banks, S. Tridandapani, Najma Mehter, Sara Guster, T. Lin, C. Eisenbeis, D. Young, J. Byrd (2006)
Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanismLeukemia, 20
-
P. Thompson, M. Keating, C. Hinojosa, Susan Smith, N. Daver, N. Jain, J. Burger, Z. Estrov, S. O'brien, W. Wierda, H. Kantarjian, A. Ferrajoli (2014)
Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II StudyBlood, 124
-
L. Bologna, E. Gotti, M. Manganini, A. Rambaldi, T. Intermesoli, M. Introna, J. Golay (2011)
Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and AlemtuzumabThe Journal of Immunology, 186
-
S. Ansell, A. Lesokhin, I. Borrello, A. Halwani, E. Scott, M. Gutierrez, S. Schuster, M. Millenson, D. Cattry, G. Freeman, S. Rodig, B. Chapuy, A. Ligon, Lili Zhu, J. Grosso, S. Kim, J. Timmerman, M. Shipp, P. Armand (2015)
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.The New England journal of medicine, 372 4
-
R. Wong, C. Pepper, P. Brennan, D. Nagorsen, S. Man, C. Fegan (2013)
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cellsHaematologica, 98
-
IF Khouri (2011)
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcomeCancer, 117
-
V. Goede, K. Fischer, R. Busch, A. Engelke, B. Eichhorst, C. Wendtner, T. Chagorova, J. Serna, M. Dilhuydy, T. Illmer, Stephen Opat, C. Owen, O. Samoylova, K. Kreuzer, S. Stilgenbauer, H. Döhner, A. Langerak, M. Ritgen, M. Kneba, E. Asikanius, K. Humphrey, M. Wenger, M. Hallek (2014)
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.The New England journal of medicine, 370 12
-
(2014)
or novel agents ?
- Publisher
- Springer Journals
- Copyright
- Copyright © 2016 by The Author(s)
- Subject
- Medicine & Public Health; Hematology; Oncology; Geriatrics/Gerontology
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- DOI
- 10.1007/s11899-015-0295-9
- pmid
- 26857283
- Publisher site
- See Article on Publisher Site
Abstract
Chronic lymphocytic leukaemia (CLL) is well known to generate impaired immune responses in the host, with the malignant clone residing in well-vascularized tissues and circulating in peripheral blood but also in close proximity to effector cells that are capable, if activated appropriately, of eliciting a cytotoxic response. These, combined with the fact that this is frequently a condition affecting older patients with co-morbidities often unfit for many “traditional” cytotoxic agents with their significant associated toxicities, make CLL an ideal candidate for the development of immunotherapy. The impressive results seen with the addition of a monoclonal antibody, rituximab, to a chemotherapy backbone, for example, is testament to how effective harnessing an immune-mediated response in CLL can be. This review serves to outline the available arsenal of immunotherapies—past and present—demonstrated to have potential in CLL with some perspectives on how the landscape in this disease may evolve in the future.
Journal
Current Hematologic Malignancy Reports – Springer Journals
Published: Feb 9, 2016